-
公开(公告)号：EP0591605B1
公开(公告)日：2001-01-10
申请号：EP93104123.0
申请日：1993-03-13
发明人： Sumi, Akinori, c/o The Green Cross Corp. , Ohtani, Wataru, c/o The Green Cross Corp. , Furuhata, Naoto, c/o The Green Cross Corp. , Takeshima, Kazuya, c/o The Green Cross Corp. , Kamide, Kaeko, c/o The Green Cross Corp. , Ohmura, Takao, c/o The Green Cross Corp. , Yokoyama, Kazumasa, c/o The Green Cross Corp.
IPC分类号： C12P21/02 , C07K14/765 , C12N15/14
CPC分类号： C12P21/02 , C07K14/765
-
2.发明公开NEOVASCULARIZATION PROMOTERS AND NEOVASCULARIZATION POTENTIATORS 有权MITTEL ZURFÖRDERUNGUNDVERSTÄRKUNGDER NEOVASKULARISIERUNG
公开(公告)号：EP1025847A1
公开(公告)日：2000-08-09
申请号：EP98940584.0
申请日：1998-08-26
发明人： EGI, Yasuhiro, Yoshitomi Pharm. Industries, Ltd , KIDO, Hideaki, Yoshitomi Pharm. Industries, Ltd , HAYASHI, Kazutaka, Yoshitomi Pharm.Industries, Ltd , KUBO, Yoshiji, Yoshitomi Pharm. Industries Ltd. , NAKAMURA, Norifumi, Yoshitomi Pharm.Industries Ltd
IPC分类号： A61K31/50
CPC分类号： C07D401/12
摘要： An angiogenesis promoter and angiogenesis potentiator containing a pyridazinone compound of the formula (I)
wherein each symbol is as defined in the specification, or a pharmacologically acceptable salt thereof, as an active ingredient. The pyridazinone compound (I) and a pharmacologically acceptable salt thereof in the present invention promote angiogenesis and potentiate the angiogenic effect of a drug having such effect, and are useful as an angiogenesis promoter and angiogenesis potentiator.摘要翻译： 含有式（I）的哒嗪酮化合物
的血管生成促进剂和血管生成增强剂，其中每个符号如说明书中所定义，或其药理学上可接受的盐作为活性成分。 本发明中的哒嗪酮化合物（I）及其药理学上可接受的盐促进血管生成并增强具有这种作用的药物的血管生成作用，并且可用作血管生成促进剂和血管生成增强剂。 -
3.发明授权Method for sterilizing recombinant human serum albumin pharmaceutical preparation 无效一种用于含白蛋白的人重组血清药物组合物的灭菌过程
公开(公告)号：EP0650736B1
公开(公告)日：2000-06-28
申请号：EP94116937.7
申请日：1994-10-26
发明人： Ohya, Tomoshi, The Green Cross Corporation , Ohda, Toyoo, The Green Cross Corporation , Kuwae, Shinobu, The Green Cross Corporation , Tomomitsu, Kenji, The Green Cross Corporation , Kobayashi, Kaoru, The Green Cross Corporation , Ohmura, Takao, The Green Cross Corporation
IPC分类号： A61L2/04
CPC分类号： C07K14/765 , A61K38/38 , A61L2/0023 , A61L2/04 , C12N7/04 , Y02A50/473
摘要： A recombinant human serum albumin (rHSA) pharmaceutical preparation is sterilized by subjecting a pharmaceutical preparation of rHSA obtained by gene manipulation techniques packed in a container in an administration unit to heat treatment at 50 to 80 DEG C for 30 minutes or more. By the disclosed method, rHSA having high safety can be provided since microorganisms contaminated in rHSA pharmaceutical preparations die as a result of the sterilization method of the present invention.
-
公开(公告)号：EP1004309A1
公开(公告)日：2000-05-31
申请号：EP98921787.2
申请日：1998-05-22
IPC分类号： A61K31/55
CPC分类号： A61K31/551 , A61K9/0043 , A61K9/0048 , A61K31/5517
摘要： Water-base preparations comprising an aqueous solution or suspension of israpafant represented by structural formula (I) and providing eye drops and nose drugs exhibiting excellent therapeutic effects against allergic conjunctivitis and rhinitis by local administration.
摘要翻译：
水溶性制剂，其包含由结构式（I）表示的异山梨醇的水溶液或悬浮液，并提供通过局部给药显示出对过敏性结膜炎和鼻炎的优异治疗效果的滴眼剂和鼻药物。 -
公开(公告)号：EP0719767B1
公开(公告)日：2000-05-03
申请号：EP94921848.1
申请日：1994-08-01
发明人： HOSONO, Hiroshi 305, Furatto-Fiirudo , NISHIO, Toshiyuki , ISHIKAWA, Hiromichi 966, Gurandohaitsu-Uozaki , NAKAMURA, Yoshiyuki 105, Haitsu-Toro , MATSUI, Tetsuo 403, Etowaru-Kasuga 2-35-2, Kasuga
IPC分类号： C07D277/64 , A61K31/425
CPC分类号： C07D277/64
摘要： A novel succinamic acid compound represented by general formula (1) or a pharmaceutically acceptable salt thereof; a preventive and/or a remedy for complications of diabetes containing the compound or the salt as the active ingredient; an aldose reductase inhibitor containing the compound or the salt as the active ingredient; and a process for producing the compound or the salt. In said formula, R1 represents alkyl or lower alkenyl, and R2 represents carboxyl which may be esterified. The invention compound (1) and the salt have a potent aldose reductase inhibitor activity on mammals including humans and an excellent safety, and hence are useful as a remedy for therapeutic treatment of complications of diabetes, such as failure of corneal lesion union, cataract, neurosis, retinopathy and nephropathy, especially cataract and neurosis. The invention process can provide the invention compounds having such a usefulness efficiently.
-
6.发明公开PROPHYLACTIC OR THERAPEUTIC AGENT FOR DISEASES ATTRIBUTABLE TO INFECTION WITH HELICOBACTERS 失效由细菌引起的用来对付疾病的预防或治疗剂引起的Helio
公开(公告)号：EP0995746A1
公开(公告)日：2000-04-26
申请号：EP98928630.7
申请日：1998-06-23
发明人： HIRAYAMA, Fumihiro, Yoshitomi Phar. Ind., Ltd. , SANO, Mitsuharu, Yoshitomi Phar. Ind. Ltd. , SAKURAI, Nobuhiro, Yoshitomi Phar. Ind. Ltd. , YOKOYAMA, Yoshito, Yoshitomi Phar. Ind. Ltd.
IPC分类号： C07D413/04 , A61K31/535
CPC分类号： A61K31/5377 , A61K31/535
摘要： The present invention relates to an agent for the prophylaxis and treatment of diseases caused by Helicobacter infections, which comprises (S)-1-cyclopropyl-1,4-dihydro-7-[2-(N,N-dimethylaminomethyl)morpholino]-6-fluoro-8-methoxy-4-oxoguinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof. The prophylactic and therapeutic agent of the present invention is effective even when used alone in a small dose for a short time, is almost free of problematic side effects such as tolerance and diarrhea, and is low toxic and capable of safe and ensured bacterial eradication. It is useful for the prophylaxis and treatment of diseases caused by Helicobacter infections, particularly, gastritis, gastric ulcer, duodenal ulcer, malignant lymphoma and gastric cancer.
摘要翻译： 本发明涉及一种用于由螺杆菌属感染引起的疾病的预防和治疗方法，其包括（S）-1-环丙基-1,4-二氢-7--A2-（N，N-二甲基氨基甲基）吗啉代OB 6的试剂 氟-8-甲氧基-4- oxoguinoline -3-羧酸或其药学上可接受的盐。 本发明的预防和治疗剂是有效的，即使当在小剂量在短时间内单独使用，几乎是无问题的副作用：如公差和腹泻，并且是低毒性的，并且能够安全并确保细菌根除。 它是用于治疗由幽门螺杆菌感染，尤其胃炎，胃溃疡，十二指肠溃疡，恶性淋巴瘤和胃癌引起的疾病的预防和治疗是有用的。
-
7.发明授权
公开(公告)号：EP0342577B1
公开(公告)日：2000-03-15
申请号：EP89108729.8
申请日：1989-05-12
发明人： Uchida, Takeshi The Green Cross Corp. , Ohtaki, Yutaka The Green Cross Corp. , Watanabe, Masahiro The Green Cross Corp. , Ashimori, Atsuyuki The Green Cross Corp. , Fukaya, Chikara The Green Cross Corp.
IPC分类号： A61K31/495
CPC分类号： A61K31/495
-
公开(公告)号：EP0974364A1
公开(公告)日：2000-01-26
申请号：EP97909616.1
申请日：1997-10-23
发明人： KODAIRA, Hideto, Yoshitomo Pharm. Ind., Ltd. , KIDO, Takae, Yoshitomo Pharmaceutical Indust.,Ltd. , NAWA, Yoshihito, Yoshitomo Pharm. Ind., Ltd. , MUNECHIKA, Koji, Yoshitomo Pharm. Ind., Ltd. , UEDA, Yasuo, Yoshitomo Pharmaceutical Indust.,Ltd.
CPC分类号： A61K9/127 , A61K9/0019 , A61K9/1075 , A61K47/14 , A61K47/24
摘要： An acidic and/or a basic drug that may precipitate in aqueous solutions such as transfusion and the like, and at least one component from phospholipid, glyceride and synthetic surfactant are admixed.
Precipitation of a drug can be inhibited, that may have a decreased solubility due to changes in pH and form precipitates. Therefore, such drug can be administered under physiological pH conditions and by mixing the drug with a transfusion having the electrolyte composition suitable for the condition of patients, and administering same to the patients.摘要翻译： 可以在诸如输血等的水溶液中沉淀的酸性和/或碱性药物以及来自磷脂，甘油酯和合成表面活性剂的至少一种组分混合。 可以抑制药物的沉淀，其可能由于pH的变化而具有降低的溶解度并形成沉淀。 因此，这种药物可以在生理pH条件下施用，并且通过将药物与具有适合患者病症的电解质组合物的输液混合并将其施用于患者。
-
9.发明公开
公开(公告)号：EP0972768A1
公开(公告)日：2000-01-19
申请号：EP98900397.5
申请日：1998-01-14
发明人： KAWASAKI, Kazuyuki;, Yoshitomi Pharm. Indus. Ltd. , KOBAYASHI, Haruhito;, Yoshitomi Pharm. Indus. Ltd , EHARA, Syuji;, Yoshitomi Pharmaceutical Ind. Ltd , SATO, Hideaki;, Yoshitomi Pharmaceutical Ind. Ltd.
IPC分类号： C07D233/60
CPC分类号： C07D231/12 , C07D233/56 , C07D249/08
摘要： The present invention provides a method for producing an optically active 4-[α-hydroxy-5-(1-imidazolyl)-2-methylbenzyl]-3,5-dimethylbenzoic acid or a pharmaceutically acceptable salt thereof, which includes subjecting a compound of the formula (I)
wherein each symbol in the formula is as defined in the specification, to optical resolution by fractional crystallization to give an optically active compound thereof and subjecting the compound to hydrolysis reaction. According to this method, a resolution method useful for industrial large-scale production of the optically active compound of 4-[α-hydroxy-5-(1-imidazolyl)-2-methylbenzyl]-3,5-dimethylbenzoic acid, which is useful as a thromboxane synthetase inhibitor and an agent for the prophylaxis and treatment of diabetic complications, can be obtained.-
10.发明授权SUSTAINED-RELEASE MICROSPHERE CONTAINING ANTIPSYCHOTIC AND PROCESS FOR PRODUCING THE SAME 无效抗精神病药物包含其制备延迟释放和方法微球
公开(公告)号：EP0669128B1
公开(公告)日：2000-01-05
申请号：EP93924827.4
申请日：1993-11-15
发明人： KINO, Shigemi, Yoshitomi Pharmaceutical Ind. Ltd. , OSAJIMA, Tomonori, Yoshitomi Pharmac. Ind. Ltd. , MIZUTA, Hiroaki, Yoshitomi Pharmaceutical Ind. Ltd
IPC分类号： A61K9/16 , A61K31/445
CPC分类号： A61K9/1647 , A61K31/40 , A61K31/445 , A61K31/4515 , A61K31/505 , A61K31/54 , A61K31/55
摘要： A sustained-release microsphere produced by enclosing a hydrophobic antipsychotic such as bromperidol or haloperidol in a base comprising a biocompatible polymer such as polylactic acid or a lactic acid/glycolic acid copolymer. It can exhibit a desired pharmacological effect, where a long-term administration is necessary, by injecting once every 1 to 8 weeks instead of every day. As a result, a remarkable improvement can be expected in the compliance during maintenance therapy. In addition, the use of the biocompatible polymer serves to entirely dispense with surgical operations such as implantation, facilitates hypodermic and intramuscular injection just like the case of suspending injection, and can dispense with the widrawal of the microsphere. Furthermore, the microsphere can be administered with little aversion and pain.
-
-
-
-
-
-
-
-
-
搜索结果
377 条记录 (耗时 0.016 秒)
